---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-044451"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2026-09-28T12:00:26+00:00"
generated_at: "2026-10-12T13:30:31.063828+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma effects 1-for-15 reverse stock split on Sept 28, 2026; CUSIP changes to 576810 402

## Summary
- Certificate of Amendment filed with Delaware on Sept 25, 2026; split effective 12:01 a.m. ET Sept 28, 2026, with NYSE American trading on a split-adjusted basis at the open.
- Every 15 shares of $0.0001 par value common stock converted into 1 share; no fractional shares issued, with holders receiving a proportional cash payment instead.
- Par value and authorized share count unchanged; outstanding options, warrants and convertible preferred stock were proportionally adjusted.
- Stockholders approved the amendment at the June 23, 2025 annual meeting; the Board authorized the filing on Sept 16, 2026.

## SEC filing metadata
- accession: 0001493152-26-044451
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2026-09-28T12:00:26+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315226044451/0001493152-26-044451-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315226044451/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-044451
- JSON: https://secwatch.observer/filing/0001493152-26-044451.json
- Plain text: https://secwatch.observer/filing/0001493152-26-044451.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.